# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
D. Boral Capital analyst Jason Kolbert maintains Omeros (NASDAQ:OMER) with a Buy and maintains $36 price target.
Omeros Corporation (NASDAQ:OMER) today announced the publication of a peer-reviewed manuscript in Blood Advances, a journal of ...
Major U.S. indices ended mixed on Wednesday, with the Dow Jones Industrial Average slipping 0.04% to 46,253.31.
Omeros stock jumps 164% as Novo Nordisk acquires global rights to zaltenibart, with potential milestones reaching $2.1 billion ...
Needham analyst Serge Belanger reiterates Omeros (NASDAQ:OMER) from Hold to Hold.